Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LA RÉUNION · Jun 1, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at the role of genetic factors, specifically a mutation in the BRCA2 gene, in breast cancer among women in Réunion. Breast cancer is a significant health concern, and researchers want to understand how common this particular mutation is in patients diagnosed with breast cancer in Réunion. By studying this mutation, they aim to improve access to genetic counseling and preventive measures for those affected.

To participate in the trial, individuals need to live in Réunion and have been diagnosed with either a first or second breast cancer. The diagnosis must be confirmed by medical tests. Participants should also be enrolled in a social security plan and agree to take part in the study. Through this trial, participants can expect to undergo genetic testing and contribute valuable information that could help better understand breast cancer in their community.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Domiciled in Reunion at the time of the diagnosis
• • Who is diagnosed with a first breast cancer (in situ or invasive) confirmed by anatomopathological examination during the inclusion period Or Who is diagnosed with a second breast cancer (in situ or invasive) confirmed by pathological examination during the inclusion period, contralateral to the first or at least 5 years after remission of the first
• • Having agreed to participate in the study;
• • Affiliates or beneficiaries of a social security scheme
• Exclusion Criteria:
• • Carriers of breast lymphoma,
• • Minor patients or patients under guardianship or curatorship